Ascensia Diabetes integrates its Eversense CGM with Apple Health

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it has updated its Eversense Continuous Glucose Monitoring system app to integrate with Apple Health.

The Parsippany, N.J.-based company makes the Contour Blood Glucose Monitoring (BGM) system and distributes Senseonics’ Eversense CGM system. The new Apple Health integration will allow people with diabetes using Senseonics’ Eversense CGM systems to view glucose data within the Apple Health app. In addition, they can also see other health metrics on the iPhone’s health and wellbeing platform.

Eversense CGM is a fully-implantable CGM with a sensor that has a 6-month sensor wear duration. The system transmits data to the Eversense CGM app. There, users can view, analyze and share glucose data. In addition, it alerts users to changes and trends in glucose levels as well.

The new integration allows users in all markets where Eversense is availab…

Read more
  • 0

Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today.

NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner.

The collaboration offers convenient at-home and in-office insertion options for diabetes patients. NPG recently completed the first patient insertion of the six-month Eversense E3 sensor in Florida. It plans to expand the initiative to other key markets across the U.S. in the coming months.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Ascensia completes Senseonics Eversense E3 European launch

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3.

Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM.

Ascensia said in a news release that its launch extends to Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands, and Andorra. The company began its phased rollout for Eversense E3 in August.

The system received CE mark approval in June.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Senseonics CFO is leaving

Senseonics (NYSE:SENS) announced that its chief financial officer, Nick Tressler, is transitioning from his position.

Tressler’s transition is effective as of yesterday, Sept. 1, 2022. Senseonics selected VP of Finance, Rick Sullivan, to succeed Tressler as CFO.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Senseonics stock is up on Q2 results

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) shares were up after hours today on second-quarter results that came up shy of the consensus forecast.

The Germantown, Maryland-based continuous glucose monitoring technology developer posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain from losses of more than $180 million this time last year on sales growth of 12.9%.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

6 drug delivery innovations you need to know

From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops.

Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies.

More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some updates on some of those technologies, plus introductions to others, here are some more impressive developments you should keep an eye on:

1. Needle-free delivery

Vaccines have become a major talking point over the past couple of years amid the COVID-19 pandemic and a number of companies are working on ways to deliver them, as well as other forms of medication, through different avenues.

A major speed bump in vaccine hesitancy can be fear of needles, so the introduction of needle-free drug delivery could make big waves in the space.

Two companies pushing forward with …

Read more
  • 0

Senseonics announces equity grants to employees

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced that it made equity grants to new employees under its 2019 inducement plan.

Germantown, Maryland-based Senseonics, which develops the Eversense family continuous glucose monitoring (CGM) systems, including the latest-generation Eversense E3 180-day CGM, made the equity grants in accordance with the NYSE American Company Guide Section 711(a).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system.

Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Senseonics beats The Street in Q1 following Eversense E3 launch

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street.

The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a sales decline of 12.8%.

Adjusted to exclude one-time items, losses per share were 3¢, falling level with projections on Wall Street, where analysts were looking for sales of $2.2 million.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Senseonics announces first Eversense E3 CGM implant in U.S.

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor.

Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S.

The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Diabetes tech is off to a hot start in 2022

Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition.

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0